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The circulatory system possesses the capability to self-heal. Proper and timely thrombosis prevents continued blood loss and maintains hemostasis within the human body. Abnormal blood clotting may result from one or more variations in the biochemical mechanism of coagulation.
Disorders of coagulation can be acquired or hereditary. Most inheritable coagulopathies result from either autosomal or X-linked mutations that encode deficiency in or nonfunctional versions of the proteins involved in coagulation. The most common coagulation disorders inherited in humans include von Willebrand disease and the hemophilias 1 [1] . Prevalent etiologies include deficiencies in the cofactors essential to proper coagulation, such as vitamins K and C [2, 3] .
Even the smallest amount of improper coagulation can pose a major risk to health.
Coagulation is intimately linked to cardiovascular health. Cardiovascular diseases, such as coronary heart disease, stroke, and deep vein thrombosis (DVT), constitute the leading cause of hospitalization and death in the United States [4] . Certain genetic variations in clotting proteins have been clinically shown to affect an individual's susceptibly to cardiovascular disease [5] . In addition to changes in lifestyle and diet, the therapeutic modulation of coagulation could serve as a method in both the prevention and intervention against certain cardiovascular diseases. Advances in the coagulation field may also improve current medical testing and certain surgical practices [6] . Research into the protein-to-protein interactions of coagulation provides insight into a biochemical process that continues to affect the livelihood of millions.
Although multiple, interrelated signals initiate thrombosis, the coagulation cascade can be generally divided into two mechanisms: the contact factor and tissue factor pathways. The tissue factor pathway predominates in vivo. Tissue factor (TF) while absent in the endothelium, is an 1 The Centers for Disease Control and Prevention estimate von Willebrand disease affects 1% of the population. The hemophilias affect 1 in 5,000 male births. Approximately 400 children are born with hemophilia each year.
integral membrane glycoprotein present in tissues of the brain, lung, blood vessel wall, and placenta. Extrinsic activation of coagulation occurs when injury allows plasma to contact cells expressing TF [7] . The pathway then proceeds with the combinatory interactions of twenty different coagulation factors to form a hard clot. Notably, monocytes and damaged endothelium within atherosclerotic plaques synthesize TF in the presence of multiple pro-inflammatory cytokines, such as tumor necrosis factor-α and interleukin1-β [8] . TF exposure and the subsequent activation of coagulation may cause rapid thrombotic blockage of blood vessels in the event of plaque rupture. Ergo, TF activation of thrombosis is consequently implicated in many cases of myocardial infarction, stroke and DVT [9] . The less critical contact factor pathway involves factor XII activation and couples with signals from the tissue factor pathway.
Both pathways converge at the multistep conversion of prothrombin (II) to α-thrombin (IIa). Figure 1 : Coagulation consists of the contact factor and tissue factor pathways, which converge to form a prothrombinase complex (FVa-FXa). FVa-FXa generates IIa from prothrombin. Various steps are dependent on Ca 2+ , phospholipid (PL), and high-molecular-weight kininogen (HK).
As demonstrated by Figure 1 , the coagulation cascade proceeds with the interactions of multiple coagulation factors. With the exception of fibrinogen and factor XIII (FXIII), the coagulation factors consist of multiple serine proteases. Sequence homology suggests most of the coagulation proteases may have arisen from a series of gene duplications [10] . Additionally, clotting proteases demonstrate active site homology with many pancreatic serine proteases involved in digestion, such as chymotrypsin, trypsin, and elastin. The activation of both digestive and clotting proteases requires the cleavage of a N-terminal propeptide, which further supports an evolutionary relationship between the two pools of serine proteases. While similarities exist between digestive proteases and many coagulation factors, both groups of enzymes appear to be regulated differently. Differential forms of regulation allow both groups of proteases to operate appropriately within a specific physiological environment.
Proper coagulation culminates in the timely formation of an ample blood clot; therefore, the cascade involves multiple levels of regulation to prevent inappropriate thrombosis. Unlike the serine proteases involved in digestion, many of the clotting factors are fully activated only in the presence of Ca 2+ and an anionic phospholipid surface. [11] . Anionic phospholipids, such as phosphatidylserine (PS) and phosphatidylethanolamine (PE), are nearly exclusive to the cytofacial leaflet of the plasma membrane [12] . Exposure of an anionic phospholipid surface occurs predominately during injury. Consequently, anionic phospholipid can attract plasma Ca 2+ .
Multiple clotting factors contain one or more γ-carboxyglutamate (Gla) binding domains that then chelate Ca 2+ ions with high affinity [2, 3] . 2 In this way, the anionic surface serves as an electrostatic docking station to collect multiple clotting factors and orients coagulation at a site of injury. Additionally, concise modulation of Ca 2+ levels in plasma can further control the extent of activation and propagation of the cascade.
The formation of a blood clot is immediately dependent on the activation and interaction of three coagulation factors: prothrombin, FXIII, and fibrinogen. In the first of two steps to form a thrombus, activated thrombin (IIa) cleaves two anionic N-terminal fibrinopeptides (A and B) from fibrinogen to form fibrin monomers [13] . Noncovalent agglomeration of multiple monomers forms a fragile clot of protofibrils. Secondly, activated FXIII mediates the covalent crosslinking of fibrin monomers to effectively convert the soft clot into a hard thrombus. The integrity of the resulting thrombus depends on multiple factors. Rate of crosslinking and incorporation of anticoagulants, such as α2-antiplasmin, have been experimentally shown to affect clot structure [14] . Given the intricate activation and interaction of these three critical factors, regulation must be equally as efficient to ensure immediate and proper thrombosis.
Prothrombin is a 579-residue zymogen present in the blood at 100 µg/mL (1.388 µM).
Human prothrombin consists of three general domains: a large N-terminal propeptide, a 36residue A chain, and a 259-residue catalytic B chain. The N-terminal propeptide, released upon prothrombin activation, is further composed of a Gla domain and two kringle domains in tandem.
A single disulfide bond persistently links the A and B chains together throughout a multistep activation process [15] . Prothrombin activation in vivo begins with cleavage of the Arg 271 -Thr272 and Arg 320 -Ile 321 peptide bonds by the FVa-FXa prothrombinase complex in the presence of Ca 2+ and anionic phospholipid. Prothrombinase cleavage facilitates the release of the propeptide and dissociation of activated thrombin from the phospholipid surface. Formed thrombin then autocleaves to trim 13 residues from the enzyme's N-terminus to generate αthrombin (IIa) [16] . IIa proceeds to serve both coagulant and anticoagulant roles.
An important role of IIa is to convert fibrinogen to fibrin. Human fibrinogen is a 340-kDa plasma glycoprotein that circulates within the blood at 2.0-4.0 mg/mL. Structurally, fibrinogen is a dimer of trimers consisting of two 610-residue Aα chains, two 461-residue Bβ chains, and two 411-residue γ chains. X-ray crystallography suggests the center regions of the α, β, and γ chains associate into a symmetric set of α-helical coiled-coils. Globular D domains hang at both ends of the molecule and a globular E domain sits between the coiled-coils [17] . Anionic fibrinopeptides (FpA and FpB) hang from the central E domain and prevent premature aggregation of the protein in circulation. Upon IIa cleavage of FpA and FpB, multiple non-covalent interactions between the D and E domains promote the agglomeration of the newly formed fibrin monomers [13] .
Fibrin formation also permits the release of the αC region of Aα fibrinogen (Fbg αC)
from the E domain. Fbg αC contains specific residues used by activated FXIII to crosslink a reactive glutamine of one fibrin monomer with a reactive lysine of another fibrin monomer [18] .
The γ chain is also crosslinked by FXIII, with γ-γ crosslinks forming faster than α-α crosslinks.
FXIII activity also affects other characteristics of a thrombus in vivo, such as the retention of red blood cells within the linked fibrin network [19, 20] . 3 Therefore, FXIII activation and interaction with fibrinogen are critical areas of study to better understand thrombogenesis in vivo. The transglutaminase factor XIII (FXIII) presents in vivo as one of two zymogens. Platelets, monocytes, and multiple cells of the placenta express FXIII as a homodimer of two 731-residue A chains (FXIII A2). Inactive plasma FXIII circulates as a tetramer composed of the two aforementioned A chains in addition to two 641-residue B chains (FXIII A2B2). Both A subunits are composed of an activation peptide, a β-sandwhich domain, two β-barrel domains, and a catalytic center. FXIII B subunits bind FXIII A subunits with a Kd of 1.0 x10 -10 M and 1% of FXIII A2 exists in the free form [21] . The association of the A and B subunits appears to increase the half-life of FXIII A2B2 in circulation. While FXIII activity serves multiple roles, the enzyme is best known to crosslink fibrin into a thrombus [22] . In plasma, IIa cleavage removes a 37-residue portion of the activation peptide to convert FXIII A2B2 to an FXIII A2′B2 intermediate. Experiments in X-ray crystallography show a subsequent Ca 2+dependent conformational change pushes both β-barrel domains away to expose and set up the FXIII active site [23] . Ca 2+ also contributes to the release of each A subunit from the corresponding B subunit (FXIII A2 * ). FXIII A2 * immediately proceeds to catalyze formation of ε-amino(γ-glutamyl)lysine isopeptide bonds between two fibrin monomers [24] . FXIII-A2 * operates via a catalytic triad similar to those of the cysteine proteases [25] .
The transglutaminase mechanism of FXIII A2 * involves attack by the catalytic cysteine thiolate on the amide group of a reactive glutamine to form a thioester linkage. Ammonia is concurrently released. Subsequently, the thioester intermediate transfers the glutamyl unit to an amine to form an amide linkage. Implicit to this mechanism is the prediction that the protein presenting the reactive glutamine localizes preferentially within FXIII A2 * through some binding interaction [26] . Putative binding sites of FXIII have been restricted to the γ 390-396 and Aα 389-403 segments of human fibrinogen [27] . 
Specific Aims
The αC region of human fibrinogen (Fbg αC) contains three reactive glutamine residues (Q237, Q328 and Q366) involved in FXIII A2 * crosslinking of the α-chains of fibrin [24] .
Studies suggest, in addition to reactive glutamines, Fbg αC may contain certain amino acids that FXIII A2 was activated by IIa in the presence of Ca 2+ . IIa was inhibited with PPACK before the introduction of GEE and Fbg αC 233-425 (WT or E396A).
Transamidation of each reactive glutamine of Fbg αC 233-425 (Q237, Q238 and Q366) by pre-activated FXIII A2 * was quantitated by a previously designed MALDI-TOF mass spectrometry strategy [24] .
AIM II: A complementary 2D 1 H-15 N HSQC NMR strategy was used to assess FXIII A2 * crosslinking of Fbg C 233-425 E396A with 15 N-labeled glycine ethyl ester.
Results from the 1 H-15 N HSQC NMR spectroscopy experiment were compared to findings for the Fbg αC 233-425 E396A mutant from the MALDI-TOF mass spectrometry studies.
AIM III: Fbg C 389-403 may contribute to FXIII activation. FXIII A2 is proposed to take longer to activate in the presence of Fbg C 233-425 E396A than in presence of the wild type. The rate of crosslinking of Q237 within the Fbg C 233-425 E396A mutant with glycine ethyl ester is proposed to be slower than the rate observed for the wild type.
IIa was introduced to a solution of FXIII A2, Fbg αC 233-425 (WT or E396A), glycine ethyl ester and Ca 2+ . Crosslinking before IIa inhibition with PPACK was monitored.
Transamidation of Q237 within Fbg αC 233-425 (E396A / WT) by FXIII-A2 * was quantified over time by an identical MALDI-TOF mass spectrometry strategy [24] . Center. DNA confirmed to contain the mutation of interest was stored for future transformation of BL-21 Gold DE3 E. coli cells.
Materials and Methods

Site-Directed Mutagenesis
BL-21 Gold DE3 Cell Transformation and Glycerol Cell Stocks
The transformation of BL-21 Gold DE3 E. coli cells was conducted over ice.
Approximately 26 ng of mutated DNA was added to 100 µL of thawed BL-21 Gold DE3 cells.
The solution was mixed and allowed to sit over ice for 30 minutes. The solution was subjected to a 45 second heat pulse in a 42℃ water bath. The reaction solution was incubated in 0.9 mL aliquot of a super optimal broth with catabolite suppression (SOC broth) for an hour before plating onto LB agar plates with ampicillin. The inoculated plates sat at 37℃ for 17 hours.
Selected colonies were chosen for small culture incubation. Three small cultures were prepared.
An IPTG test was conducted to assess the prolificacy of each small culture. The fastest growing culture was selected to make glycerol stocks. Cell stocks were made by first aliquoting 100 µL of cooled, autoclaved 50% glycerol into a 1.5 mL tube. 100 µL of BL-21 Gold DE3 cell culture was added to each solution of glycerol. Stocks were mixed gently and frozen at -80℃. After incubation, the two large BL21 Gold DE3 cell cultures were divided evenly and balanced within six 500 mL Beckman centrifuge bottles. Cells were spun down in a Beckman JA-10 centrifuge rotor at 3317 g for 10 minutes at 4℃. The supernatants were decanted and subsequently bleach treated. The resulting pellets were then suspended in 360 mL of an E. coli wash buffer. The suspension was divided equally among eight 50 mL VWR centrifuge tubes.
GST-Fbg
Tubes were spun at 5000 g in an Allegra R-20 swinging-bucket centrifuge for 1 hour at 4℃. The supernatants were discarded and bleach treated. A total of eight E. coli cell pellets were frozen at -20C for future protein extraction. were further concentrated into stock solutions using a VivaSpin centrifugal concentrator with molecular weight cut-off of 30 kDa. 4 PreScission Protease is a fusion protein of the human rhinovirus protease and GST that facilitates the specific cleavage between the Gln and Gly residues of the sequence Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro. MALDI-TOF MS assessed whether the fragments previously monitored to quantitate FXIII A2 * crosslinking of the Fbg αC 233-425 wild type could be detected to similar extents when using the Fbg αC 233-425 E396A mutant. Analysis revealed the same three peptide fragments appear after the GluC and chymotrypsin digests of Fbg αC 233-425 E396A and wild type [24] . An additional peptide that previously contained E396 in the wild type decreased by a mass expected after Gln to Ala mutation (2704. 78 in the wild type to 2647.78 Da in Fbg αC 233-425 E396A). with R158 within the activation cleft of FXIII A2 * [23] . Authors proposed that structural effects caused by a salt bridge between Fbg αC E396 and FXIII A2 * facilitates the observed binding.
AIM I: MALDI-TOF Mass Spectrometry
An enzyme-linked immunoabsorbant assay (ELISA) and a FXIII A2 * 5-(biotinamido) Fbg αC segment should cause decreased association and reactivity of FXIII A2 * [23, 26] . The work presented herein assessed the effect of the E396A mutation within Fbg αC 389-402 on the crosslinking of three natural substrates (Fbg αC Q237, Q328, and Q366) by FXIII A2 * .
Results of three reactivity studies indicate mutation at Fbg αC E396 does not affect FXIII A2 * reactivity towards the three reactive glutamines of Fbg αC 233-425. Complementary assays utilizing MALDI-TOF mass spectrometry and 1 H-15 N HSQC NMR spectroscopy confirm FXIII A2 * crosslinked Fbg αC 233-425 E396A with glycine ethyl ester. Additionally, pre-activated FXIII A2 * was shown to crosslink the three reactive glutamines of Fbg αC 233-425 E396A at rates comparable to the rates previously seen with the wild type under identical conditions [24] .
These results question the extent to which the interactions proposed by Smith et al. between Fbg Aα and FXIII influence the reactivity of FXIII A2 * towards Fbg αC Q237, Q328, and Q366.
A second MALDI-TOF mass spectrometry assay revealed FXIII A2, when incubated with its substrates, activates and subsequently crosslinks Q237 of Fbg αC 233-425 E396A and the wild type with glycine ethyl ester at similar rates. When taken together, the three studies presented indicate the loss of Fbg αC E396 does not influence either activation of FXIII A2 to FXIII A2 * or the ability of FXIII A2 * to recognize and bind to Fbg αC 233-425. Given the information presented, results could be interpreted two different ways. Firstly, if Fbg αC E396 contributes to a putative FXIII binding site, the electrostatic interaction proposed by Smith et al.
between Fbg αC E396 and FXIII A2 * R158 must not be required for the proper transglutaminase activity of FXIII A2 * [23] . Alternatively, additional structural details of the natural Fbg αC 233-425 segment must exist to successfully compensate for the loss of Fbg αC E396 to FXIII A2 * R158 interaction and any consequential structural changes.
In addition to documenting interactions of FXIII A2 * and Fbg C 233-425, Smith et. al have identified a high-affinity interaction between FXIII A2B2 and Fbg C 371-425 [26] . FXIII A2B2 binding to Fbg αC appears to occur before and after IIa cleavage of the FXIII activation peptides. Future work should assess whether the presence of FXIII B2 subunits target this putative FXIII binding site of Fbg Aα to modulate either FXIII A2B2 activation or reactivity towards Fbg C Q237, Q328, Q366.
Conclusions
Three reactivity experiments indicate an E396A mutation within Fbg αC 233-425 does not influence either the activation of FXIII A2 to FXIII A2 * or the ability of FXIII A2 * to recognize and bind Fbg αC 233-425. Although Fbg αC E396 contributes to a putative FXIII binding site, a proposed interaction between Fbg αC E396 and FXIII A2 * R158 is not required for the proper transglutaminase activity of FXIII A2 * . Alternatively, additional structural components of the natural FXIII A2 substrate, Fbg αC 233-425, could exist to compensate for the loss of Fbg αC E396 to FXIII A2 * R158 interaction and any consequential structural changes.
